1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials
BJORNSTAD P, DANNE T, TAMBORLANE W, KLINGENSMITH G, SCHUELER E, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S, LAFFEL L. 1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials. Diabetes 2024, 73 DOI: 10.2337/db24-1140-p.Peer-Reviewed Original ResearchDiabetic kidney diseaseKidney diseaseHoc analysisDiabetic kidney disease riskEarly diabetic kidney diseaseBaseline to weekImpact of empagliflozinCystatin C equationClinically relevant improvementNational Institute of DiabetesDigestive and Kidney DiseasesPost hoc analysisEGFR changeIncreased riskHyperfiltrationPubertal statusGlycemic controlEGFRC equationLong-term effectsPotential long-term effectsRelevant improvementNormofiltrationT2DHealthy youth